Evidence-based medicine: Application in Alzheimer's disease research

Journal of Alzheimer's Disease

Volumn 20, Issue 3, 2010, Pages 935-942

  Murad, M Hassan ^a   Montori, Victor M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Alzheimer's disease; evidence based medicine; patients' values and preferences; quality of evidence; research methodology

Indexed keywords

ALUMINUM; CHOLINESTERASE INHIBITOR; CYANOCOBALAMIN; DONEPEZIL; FOLIC ACID; GALANTAMINE; MEMANTINE; PLACEBO; POLYUNSATURATED FATTY ACID; RIVASTIGMINE;

AGE; ALUMINUM BLOOD LEVEL; ALZHEIMER DISEASE; CLINICAL DECISION MAKING; CLINICAL RESEARCH; COGNITION; CONFIDENCE INTERVAL; DEMENTIA; DISEASE COURSE; DOSE RESPONSE; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; EYE DOMINANCE; FOLLOW UP; HUMAN; KNOWLEDGE; METHODOLOGY; MILD COGNITIVE IMPAIRMENT; OUTCOME ASSESSMENT; PARAMEDICAL PERSONNEL; PATIENT; POLICY; PRIORITY JOURNAL; PUBLISHING; RECALL BIAS; RESOURCE ALLOCATION; REVIEW; RISK; STUDY DESIGN;

EID: 77954561381     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1419     Document Type: Review

References (37)

1. (1981) How to read clinical journals, I: why to read them and how to start reading them critically. Can Med Assoc J 124, 555-558.
2. Guyatt G (1991) Evidence based medicine. ACP J Club 114, A-16.
3. Sackett D, Straus S, Richardson S, Rosenberg W, Haynes R (2000) Evidence-Based Medicine: How to Practice and Teach EBM. Churchill Livingstone London.
4. Guyatt G, Haynes B, Jaeschke R, Meade M, Wilson M, Montori V, Richardson S (2008) The philosophy of evidence based medicine. In Users' Guides to the Medical Literature, Guyatt G, Rennie D, Meade M, Cook D, eds. McGraw-Hill, New York.
5. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280, 605-613.
6. Writing Group for the WHI Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333.
7. Griesdale D, de Souza R, van Dam R, Heyland D, Cook D, Malhotra A, Dhaliwal R, Henderson W, Chittock D, Finfer S, Talmor D (2009) Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICESUGAR study data. CMAJ 180, 821-827.
8. Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso- Coello P, Schünemann H, for the GRADE Working Group (2008) Rating quality of evidence and strength of recommendations. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336, 924-926.
9. Antman EM LJ, Kupelnick B, Mosteller F, Chalmers TC (1992) A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA 268, 240-248.
10. Guyatt G, Oxman A, Kunz R, Vist G, Falck-Ytter Y, Schünemann H, for theGRADEWorking Group (2008) Rating quality of evidence and strength of recommendations. What is "quality of evidence" and why is it important to clinicians? BMJ 336, 995-998.
11. Lee P (1994) Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 13, 131-144.
12. Kukull W (2001) The association between smoking and Alzheimer's disease: effects of study design and bias. Biol Psychiatry 49, 194-199.
13. Almeida O, Hulse G, Lawrence D, Flicker L (2002) Smoking as a risk factor for Alzheimer's disease: contrasting evidence from a systematic review of case-control and cohort studies. Addiction 97, 15-28.
14. Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, O'Brien J, Everratt A, Sadler S, Maddison C, Lee L, Bannister C, Elvish R, Jacoby R (2005) Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 330, 874.
15. Jones R, Soininen H, Hager K, Aarsland D, Passmore P, The DONGAL Study Group, Murthy A, Zhang R, Bahra R (2004) A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 19, 58-67.
16. Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y, Bullock R, Members of the GAL-GBR-2 Study Group (2003) A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 20, 777-789. (Pubitemid 36995254)
17. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148, 379-397.
18. Montori VM, Smieja M, Guyatt GH (2000) Publication bias: a brief review for clinicians. Mayo Clin Proc 75, 1284-1288.
19. García A, Sisternas A, Hoyos S (2008) Occupational exposure to extremely low frequency electric and magnetic fields and Alzheimer disease: a meta-analysis. Int J Epidemiol 37, 329-340.
20. Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I (2006) The case of the misleading funnel plot. BMJ 333, 597-600.
21. Gandhi GY, Murad MH, Fujiyoshi A, Mullan RJ, Flynn DN, Elamin MB, Swiglo BA, Isley WL, Guyatt GH, Montori VM (2008) Patient-important outcomes in registered diabetes trials. JAMA 299, 2543-2549.
22. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt F (2009) Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 3, CD001191.
23. SummersW, DeBoyntonV, Marsh G, MajovskiL(1990) Comparison of seven psychometric instruments used for evaluation of treatment effect in Alzheimer's dementia. Neuroepidemiology 9, 193-207.
24. Mendiondo M, Ashford J, Kryscio R, Schmitt F (2000) Modelling Mini Mental State Examination changes in Alzheimer's disease. Statist Med 19, 1607-1616.
25. Hansen R, Gartlehner G,Webb A, Morgan L, Moore C, Jonas D (2008) Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 3, 211-225.
26. Bucher H, Guyatt G, Griffith L,Walter S (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50, 683-691.
27. Higgins J, Thompson S, Deeks J, Altman D (2003) Measuring inconsistency in meta-analyses. BMJ 327, 557-560.
28. Profenno L, Porsteinsson A, Faraone S (2010) Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry 67, 505-512.
29. Diniz B, Pinto JJ, Gonzaga M, Guimaräes F, Gattaz W, Forlenza O (2009) To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impair ment for delaying progression to Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 259, 248-256.
30. Rockwood K (2004) Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry 75, 677-685.
31. Polizzi S, Pira E, Ferrara M, Bugiani M, Papaleo A, Albera R, Palmi S (2002) Neurotoxic effects of aluminium among foundry workers and Alzheimer's disease. NeuroToxicology 23, 761-774.
32. Luchsinger J, Tang M, Miller J, Green R, Mayeux R (2007) Relation of higher folate intake to lower risk of Alzheimer disease in the elderly. Arch Neurol 64, 86-92.
33. Psaltopoulou T, Kyrozis A, Stathopoulos P, Trichopoulos D, Vassilopoulos D, Trichopoulou A (2008) Diet, physical activity and cognitive impairment among elders: the EPIC - Greece cohort (European Prospective Investigation into Cancer and Nutrition). Public Health Nutr 11, 1054-1062.
34. Guyatt G, Oxman A, Kunz R, Falck-Ytter Y, Vist G, Liberati A, Schünemann H, GRADE Working Group (2008) Rating quality of evidence and strength of recommendations: Going from evidence to recommendations. BMJ 336, 1049-1051.
35. Qaseem A, Snow V, Cross JT, Jr., Forciea MA, Hopkins R, Jr., Shekelle P, Adelman A, Mehr D, Schellhase K, Campos- Outcalt D, Santaguida P, Owens DK, American College of Physicians/American Academy of Family Physicians Panel on D (2008) Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. [summary for patients in Ann Intern Med. 2008 Mar 4;148(5):I41; PMID: 18316749]. Ann Int Med 148, 370-378.
36. Karanicolas P, Montori V, Devereaux P, Schünemann H, Guyatt G (2009) A new "mechanistic-practical" framework for designing and interpreting randomized trials. J Clin Epidemiol 62, 479-484.
37. Redelmeier DA, Guyatt GH, Goldstein RS (1996) Assessing the minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol 49, 1215-1219.